Search the Newsreel

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Immunotherapeutics announced positive Week 16 topline results from its Phase 3 IZAR-1 trial for sonelokimab in biologic-naïve adults with active psoriatic arthritis, meeting all primary and secondary clinical endpoints. Despite the positive results, the stock fell over 6%. The company also reported strong …

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3% - Time to Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Estimates By $0.08 EPS

MoonLake Immunotherapeutics (MLTX) deepens loss but ends H1 2026 with $537M cash and key Phase 3 wins

MoonLake Immunotherapeutics (MLTX) Projected to Release Earnings on Tuesday

HC Wainwright Issues Positive Estimate for MLTX Earnings

MoonLake Immunotherapeutics CSO Kristian Reich disposes of $1 million in common shares

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 52,448 Class A ordinary shares totaling approximately $1 million on July 21-22. The shares were sold at prices of $20.02 and $20 per share. Following these transactions, his indirect holdings decreased to 2,712,298 shares, while …

Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX)

Jerucon Beratungsgesellschaft mbH has filed a Form 144 notice to sell 150,000 Class A Ordinary shares of MoonLake Immunotherapeutics (MLTX) through UBS Financial Services, Inc. on or after July 15, 2026, for an aggregate value of $2,916,000. This filing also reports previous sales by …

MoonLake Immunotherapeutics (NASDAQ: MLTX) raises $30M via option exercise

MoonLake Immunotherapeutics announced that underwriters fully exercised their option to purchase an additional 1,500,000 Class A ordinary shares as part of a previously announced public offering. This exercise, which closed on July 14, 2026, generated an additional $30.0 million in gross proceeds for the …